develop
effect
vaccin
sever
acut
respiratori
syndrom
sar
remain
prioriti
prevent
possibl
reemerg
sar
coronaviru
sarscov
previous
demonstr
receptorbind
domain
rbd
sarscov
protein
major
target
neutral
antibodi
suggest
rbd
may
serv
ideal
vaccin
candid
recombin
adenoassoci
viru
raav
proven
effect
system
gene
deliveri
vaccin
develop
studi
novel
vaccin
sarscov
develop
base
raav
deliveri
system
gene
encod
rbd
clone
paavireshrgfp
plasmid
immunogen
induc
result
recombin
rbdraav
evalu
balbc
mice
result
demonstr
singl
dose
rbdraav
vaccin
could
induc
suffici
neutral
antibodi
sarscov
infect
two
repeat
dose
vaccin
boost
neutral
antibodi
time
level
achiev
singl
dose
immun
level
antibodi
continu
increas
entir
durat
experi
month
result
suggest
rbdraav
promis
sar
candid
vaccin
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
identifi
etiolog
agent
newli
emerg
infecti
diseas
sar
ksiazek
et
al
marra
et
al
peiri
et
al
rota
et
al
although
sar
appear
success
contain
reemerg
diseas
rule
support
fact
four
laboratoryacquir
four
communityacquir
sar
case
report
singapor
taiwan
china
sar
outbreak
wwwwhointcsrsarsen
therefor
develop
effect
vaccin
sar
urgent
need
sarscov
singlestrand
posit
rna
viru
whose
genom
encod
nonstructur
replicas
polyprotein
rep
structur
protein
spike
envelop
e
membran
nucleocapsid
n
anand
et
al
marra
et
al
rota
et
al
protein
recogn
bind
host
receptor
conform
chang
induc
viral
protein
would
facilit
fusion
viral
envelop
host
cell
membran
thu
play
pivot
role
viral
infect
pathogenesi
hofmann
et
al
holm
yu
et
al
zheng
et
al
protein
type
transmembran
glycoprotein
consist
domain
bosch
et
al
holm
enjuan
krokhin
et
al
ying
et
al
fig
domain
determin
host
cell
tropism
attach
cell
receptor
domain
mainli
respons
viru
cell
membran
fusion
bosch
et
al
gallagh
buchmeier
angiotensinconvert
enzym
identifi
function
receptor
sarscov
dimitrov
prabakaran
et
al
fragment
contain
residu
region
found
minim
receptorbind
domain
rbd
babcock
et
al
wong
et
al
xiao
et
al
fig
second
major
properti
sarscov
protein
induc
neutral
antibodi
protect
immun
bisht
et
al
buchholz
et
al
bukreyev
et
al
yang
et
al
yang
et
al
report
dna
vaccin
encod
protein
abl
induc
tcell
neutralizingantibodi
respons
neutral
antibodi
titer
rang
prove
protect
mice
sarscov
challeng
mediat
neutral
antibodi
tcelldepend
mechan
traggiai
et
al
demonstr
protect
immun
mice
could
achiev
sole
administr
neutral
monoclon
antibodi
specif
protein
data
suggest
effect
sar
vaccin
develop
base
abil
induc
neutral
antibodi
previous
report
rbd
sarscov
protein
abl
elicit
potent
neutral
antibodi
rabbit
et
al
furthermor
rbd
also
found
immunogen
domain
sarscov
induc
neutral
antibodi
sarscov
infect
patient
et
al
therefor
protein
especi
rbd
domain
good
target
develop
vaccin
sar
et
al
adenoassoci
viru
aav
power
deliveri
vector
wide
use
gene
therapi
chao
et
al
kaspar
et
al
tsai
et
al
high
transduct
effici
minim
viral
toxic
broad
rang
infect
littl
pathogenesi
human
aav
system
success
appli
studi
gene
immun
therapi
mani
diseas
keir
et
al
lieber
furthermor
longterm
gene
transfer
express
varieti
cell
type
organ
made
system
ideal
choic
develop
recombin
vaccin
tomar
et
al
present
studi
use
aav
vector
deliv
gene
express
rbd
sarscov
protein
rbdraav
effect
singl
dose
multipl
dose
rbdraav
vaccin
evalu
balbc
mice
induc
sarscovspecif
antibodi
especi
neutral
antibodi
gener
recombin
aav
transfect
cell
sarscov
protein
glycoprotein
consist
domain
domain
contain
signal
peptid
sp
nterminu
rbd
aa
domain
contain
heptad
repeat
fig
schemat
diagram
protein
sarscovand
prbdaav
structur
sarscov
protein
domain
sp
rbd
rang
aa
aa
aa
aa
respect
domain
contain
function
domain
tm
dna
encod
aa
signal
peptid
aa
rbd
sarscov
protein
amplifi
ligat
paavireshrgfp
plasmid
construct
recombin
prbdaav
vector
b
transmembran
domain
tm
fig
construct
prbdaav
vector
nucleotid
sequenc
encod
sp
replac
latter
ligat
rbd
sequenc
sarscov
chimer
gene
subclon
multipl
clone
site
mc
paavireshrgfp
plasmid
stratagen
usa
fig
result
prbdaav
plasmid
blank
paav
plasmid
cotransfect
cell
togeth
paavrc
phelper
plasmid
produc
aav
harbor
chimer
gene
rbdraav
harbor
chimer
gene
blank
aav
intens
fluoresc
human
recombin
green
fluoresc
protein
hrgfp
rbdaav
fig
blank
aav
fig
observ
transfect
cell
fluoresc
microscopi
h
posttransfect
illustr
high
transfect
effici
viral
plasmid
cell
yield
either
rbdraav
blank
aav
respect
transfect
cell
harvest
mm
tissu
cultur
dish
purifi
titer
estim
realtim
quantit
pcr
viral
particlesml
fig
compar
transduct
rbdraav
blank
aav
hela
cell
experi
hela
cell
inocul
serial
dilut
virus
h
incub
extent
infect
either
viru
assess
level
gfp
hrgfp
express
cell
use
fluoresc
microscopi
flow
cytometri
analysi
fluoresc
microscopi
show
cell
infect
raav
fig
numer
hela
cell
fig
shown
fig
flow
cytometri
analysi
estim
cell
infect
rbdraav
infect
blank
aav
substanti
higher
level
infect
achiev
hela
cell
rbdraav
blank
aav
result
confirm
find
romano
et
al
show
infect
effici
aav
vector
differ
differ
cell
anoth
experi
percentag
infect
cell
enumer
differ
time
infect
fig
result
show
percentag
rbdraavinfect
cell
detect
differ
time
close
parallel
percentag
blank
aavinfect
cell
percentag
hela
cell
infect
either
virus
b
show
rbd
insert
affect
effici
raav
infect
express
express
rbd
rbdraav
infect
hela
cell
detect
immunofluoresc
assay
western
blot
assay
result
show
monoclon
antibodi
specif
sarscov
react
cell
infect
rbdaav
fig
infect
blank
aav
fig
express
rbd
also
detect
western
blot
lysat
cell
infect
rbdraav
lysat
cell
infect
blank
aav
fig
result
demonstr
rbdraav
abl
effici
express
insert
rbd
gene
infect
cell
singl
dose
rbdraav
vaccin
induc
suffici
sarscovspecif
antibodi
respons
neutral
activ
mice
group
balbc
mice
vaccin
singl
dose
rbdraav
blank
aav
neg
control
inactiv
sarscov
suspend
pb
adjuv
alum
posit
control
anim
bled
immun
month
postvaccin
level
sarscovspecif
antibodi
serum
sampl
determin
elisa
shown
fig
titer
sarscovspecif
antibodi
sera
singl
dose
rbdraav
immun
mice
reach
mean
se
month
slightli
increas
month
postvaccin
comparison
level
sarscov
antibodi
induc
inactiv
viru
vaccin
peak
earlier
month
postimmun
slightli
low
level
alum
p
significantli
low
level
without
alum
p
month
postimmun
sarscov
neutral
activ
mous
sera
test
neutral
assay
vero
cell
accord
method
describ
qu
et
al
anim
vaccin
rbdraav
fig
show
neutral
antibodi
level
rose
continu
month
month
postvaccin
comparison
antibodi
level
anim
given
inactiv
viru
vaccin
peak
earlier
month
immun
peak
level
neutral
antibodi
anim
vaccin
rbdraav
similar
vaccin
inactiv
viru
suspend
alum
p
almost
higher
given
inactiv
viru
suspend
pb
p
sarscov
neutral
antibodi
could
detect
mous
sera
blank
aav
immun
group
result
indic
although
rbdraav
vaccin
induc
lower
level
neutral
antibodi
vaccin
sarscov
plu
alum
month
immun
deliv
prolong
effect
increas
neutral
antibodi
titer
month
postvaccin
similar
higher
inactiv
viru
vaccin
without
alum
p
experi
group
mice
given
repeat
dose
rbdraav
blank
aav
neg
control
inactiv
sarscov
without
adjuv
alum
posit
control
anim
bled
differ
time
period
month
follow
first
dose
anim
given
rbdraav
vaccin
level
sarscovspecif
antibodi
determin
elisa
increas
continu
throughout
experi
reach
titer
month
postvaccin
fig
anim
given
inactiv
viru
antibodi
level
reach
peak
without
alum
alum
month
postvaccin
antibodi
level
determin
end
experi
month
first
dose
slightli
higher
anim
given
rbdraav
vaccin
given
inactiv
viru
differ
statist
signific
p
neutral
antibodi
level
rbdraav
group
anim
also
rose
continu
throughout
durat
experi
month
level
elisa
antibodi
wherea
antibodi
level
anim
receiv
inactiv
viru
vaccin
peak
month
end
experi
month
first
dose
neutral
antibodi
level
rbdraav
group
similar
peak
antibodi
level
anim
given
inactiv
viru
vaccin
without
alum
alum
time
higher
antibodi
level
induc
singl
dose
vaccin
see
fig
sera
rbdraavvaccin
mice
suppress
rbd
bind
receptor
sera
mice
immun
rbdraav
detect
inhibitori
activ
bind
rbd
sarscov
receptor
competit
assay
shown
fig
sera
five
rbdraav
immun
mice
abl
suppress
rbd
bind
none
preimmun
sera
sera
blank
aav
immun
mice
inhibit
bind
result
concur
occurr
sarscov
neutral
antibodi
impli
rbdraav
vaccin
could
evok
protect
immun
viru
develop
sar
vaccin
urgent
requir
prevent
reemerg
sar
sever
approach
develop
sar
vaccin
report
includ
inactiv
vaccin
et
al
qu
et
al
dna
vaccin
zeng
et
al
recombin
proteinbas
vaccin
bisht
et
al
bisht
et
al
et
al
attenu
modifi
vaccinia
viru
ankara
mva
base
vaccin
adenovirusbas
vaccin
gao
et
al
b
rhabdovirusbas
vaccin
faber
et
al
candid
vaccin
could
induc
sarscovspecif
immun
respons
andor
elicit
protect
neutral
antibodi
respons
immun
anim
studi
construct
anoth
sar
vaccin
base
aav
fig
detect
rbd
express
rbdraav
infect
cell
immunofluoresc
assay
western
blot
analysi
express
rbd
rbdraav
blank
aav
b
infect
hela
cell
test
immunofluoresc
assay
rbd
express
also
detect
western
blot
c
lane
rbdraavinfect
hela
cell
lysat
lane
blank
aavinfect
hela
cell
lysat
molecular
marker
kda
indic
left
molecular
mass
express
rbd
protein
kda
immun
respect
one
dose
rbdraav
blank
aav
inactiv
sarscov
inscov
alum
without
inscov
alum
serum
sampl
collect
mice
prevaccin
month
month
postimmun
sarscovspecif
antibodi
serum
sampl
detect
elisa
use
commerci
sarscov
antibodi
detect
kit
neutral
antibodi
titer
sera
measur
neutral
assay
b
experi
repeat
four
time
rbdraav
group
two
time
group
data
present
mean
valu
se
deliveri
system
evalu
immunogen
mous
model
sarscov
protein
known
respons
induc
host
immun
respons
viru
neutral
antibodi
sar
infect
gao
et
al
hofmann
et
al
nie
et
al
yang
et
al
zheng
et
al
report
neutral
antibodi
sarscov
protein
abl
provid
protect
sarscov
infect
bisht
et
al
bukreyev
et
al
sui
et
al
although
multipl
fragment
protein
shown
abl
elicit
neutral
activ
keng
et
al
zhang
et
al
rbd
receptorbind
domain
function
viru
receptor
contain
multipl
conformationdepend
epitop
effect
induc
highli
potent
protect
neutral
antibodi
et
al
et
al
recent
studi
also
demonstr
rbd
region
main
target
elicit
neutral
antibodi
inactiv
sarscov
immun
rabbit
import
immunogen
site
patient
infect
sarscov
therefor
rbd
sarscov
protein
select
target
immunogen
studi
develop
sarscov
vaccin
construct
prbdaav
vector
rbd
gene
sarscov
codonoptim
codonoptim
use
strategi
improv
protein
express
enhanc
immunogen
dna
vaccin
mani
virus
mycobacteria
cheung
et
al
ko
et
al
moor
et
al
ramakrishna
et
al
smith
et
al
wang
et
al
b
report
gao
et
al
shown
codonoptim
could
increas
level
express
enhanc
immunogen
structur
gene
human
immunodefici
viru
type
frelin
et
al
also
indic
codonoptim
hepat
c
viru
hcv
gene
result
improv
immunogen
hcvbase
vaccin
although
compar
effici
codonoptim
rbd
gene
wildtyp
rbd
gene
studi
high
effici
rbdraav
vaccin
may
partial
attribut
express
immunogen
rbd
improv
codonoptim
reason
aav
use
deliv
express
rbd
gene
studi
demonstr
promis
tool
deliveri
foreign
gene
due
advantag
high
viru
product
broad
host
rang
without
caus
known
human
diseas
stilwel
samulski
wang
et
al
result
show
high
viral
particlesml
rbdraav
could
produc
transfect
cell
also
confirm
recombin
rbdraav
abl
effici
infect
differ
cell
line
fig
express
rbd
protein
transduc
cell
line
recogn
sarscov
neutral
mcab
fig
mous
model
vaccin
singl
dose
rbdraav
elicit
high
level
sarscovspecif
antibodi
especi
neutral
antibodi
reach
mean
titer
month
postimmun
higher
induc
inactiv
viru
vaccin
without
alum
fig
demonstr
mous
sera
induc
rbdraav
vaccin
abl
effect
suppress
rbd
bind
fig
fig
detect
specif
antibodi
respons
three
dose
rbdraavvaccin
mice
sarscovspecif
antibodi
respons
mice
vaccin
three
dose
rbdraav
control
test
elisa
neutral
assay
b
serum
sampl
collect
mice
prevaccin
month
month
postimmun
experi
repeat
two
time
data
present
mean
valu
se
fig
inhibitori
test
rbd
bind
sera
obtain
five
mice
vaccin
dose
rbdraav
label
month
postvaccin
detect
inhibitori
effect
bind
rbd
elisa
sera
five
mice
immun
dose
blank
aav
appli
assay
neg
control
serum
sampl
test
duplic
data
present
mean
valu
two
test
suggest
neutral
activ
mediat
inhibit
viru
bind
receptor
host
cell
membran
report
level
sarscov
neutral
antibodi
found
convalesc
sera
recov
sar
patient
rang
zheng
et
al
anoth
studi
also
show
titer
sarscov
neutral
antibodi
elicit
recombin
attenu
modifi
vaccinia
viru
ankara
mva
encod
sar
protein
protect
immun
mice
sarscov
challeng
bisht
et
al
result
suggest
one
dose
vaccin
rbdraav
may
provid
suffici
protect
sarscov
infect
found
viral
deliveri
system
ie
adenoviru
vaccinia
viru
system
primari
immun
could
induc
host
immun
deliveri
viral
particl
would
affect
efficaci
subsequ
repeat
vaccin
liu
muruv
muruv
nasz
adam
howev
result
show
primari
vaccin
rbdraav
affect
repeat
vaccin
neutral
antibodi
level
markedli
increas
mice
boost
twice
reach
mean
titer
higher
mice
receiv
one
dose
vaccin
fig
may
attribut
low
antigen
aav
deliveri
vector
use
studi
minim
host
immun
respons
deliveri
vector
compar
inactiv
sarscov
immun
sarscovspecif
antibodi
induc
either
singl
dose
repeat
rbdraav
vaccin
reach
highest
level
least
month
later
vaccin
abl
stimul
mice
continu
produc
sarscovspecif
antibodi
increas
neutral
activ
least
end
point
experi
month
singl
dose
month
repeat
dose
indic
rbdraav
vaccin
deliv
prolong
immun
respons
fig
may
due
gene
express
recombin
aav
goe
slow
onset
firstli
take
cours
day
week
follow
persist
gene
express
mani
month
support
report
aav
may
longterm
express
foreign
gene
vivo
differ
organ
without
result
signific
toxic
monahan
samulski
rabinowitz
samulski
smitharica
bartlett
howev
conclud
antibodi
respons
reach
highest
level
studi
end
time
long
high
level
specif
antibodi
maintain
rbdraavvaccin
mice
monitor
antibodi
respons
month
postimmun
summari
studi
demonstr
live
aav
deliveri
system
effect
tool
deliveri
express
rbd
gene
sarscov
mous
model
singl
dose
intramuscular
immun
rbdraav
induc
viralspecif
antibodi
respons
whose
titer
significantli
higher
inactiv
viru
vaccin
repeat
vaccin
elicit
prolong
immun
respons
result
increas
sarscov
neutral
antibodi
vaccin
mice
end
point
studi
anoth
advantag
vaccin
base
live
aav
deliveri
system
may
use
mucos
immun
induc
local
immun
respons
report
high
titer
fecal
hivspecif
iga
neutral
antibodi
detect
hivraav
immun
mice
xin
et
al
studi
rbdraav
intranas
vaccin
progress
demonstr
feasibl
live
aav
recombin
vaccin
develop
sar
vaccin
gene
encod
rbd
sarscov
protein
codon
optim
use
overlap
primer
accord
method
describ
previous
gao
et
al
et
al
fig
codon
optim
rbd
gene
clone
vector
takara
japan
use
templat
firstround
pcr
forward
primer
revers
primer
xhoi
restrict
enzym
site
underlin
stop
codon
amplifi
rbd
fragment
use
templat
secondround
pcr
amplifi
gene
signal
peptid
ligat
rbd
product
use
forward
primer
bamhi
restrict
site
underlin
start
codon
label
bold
revers
primer
first
round
amplifi
digest
bamhi
xhoi
subclon
mc
paavireshrgfp
vector
hrgfp
novel
marin
organ
express
second
open
read
frame
serv
indic
express
insert
rbd
gene
evalu
effici
transfect
infect
subsequ
experi
fig
construct
recombin
plasmid
name
prbdaav
rbdraav
blank
aav
gener
use
aavhelperfreesystem
follow
manufactur
instruct
stratagen
usa
briefli
day
transfect
cell
seed
tissu
cultur
dish
maintain
dulbecco
modifi
eagl
medium
dmem
invitrogen
usa
suppli
fetal
calf
serum
fc
invitrogen
usa
cell
provid
adenoviru
gene
reach
confluenc
prbdraav
paav
plasmid
cotransfect
phelper
plasmid
provid
adenoviru
va
rna
gene
paavrc
plasmid
provid
repcap
gene
calcium
phosphat
transfect
method
stratagen
usa
transfect
cell
cultur
co
fresh
medium
ad
h
later
cultur
supernat
transfect
cell
harvest
h
transfect
produc
aav
purifi
accord
wu
et
al
modif
harvest
cell
lyze
sonic
shaken
h
ad
chloroform
nacl
respect
moll
supernat
incub
final
concentr
ice
h
solut
cell
lysat
supernat
centrifug
rpm
min
pellet
resuspend
phosphatebuff
salin
pb
buffer
ph
incub
dnase
rnase
final
concentr
ice
min
follow
ad
equal
volum
chloroform
aqueou
phase
contain
purifi
aav
collect
centrifug
rpm
min
store
use
titer
gener
aav
determin
realtim
quantit
pcr
use
forward
primer
revers
primer
briefli
purifi
viru
stock
treat
proteas
k
sodium
dodecyl
sulfat
sd
final
concentr
mgml
respect
viral
dna
extract
use
dna
extract
kit
invitrogen
usa
viral
dna
serial
dilut
mix
primer
lightercycl
faststart
reaction
sybr
green
reagent
roch
usa
realtim
quantif
carri
lightcycl
system
roch
usa
condit
min
cycl
follow
prbdaav
plasmid
serial
dilut
use
standard
control
infect
purifi
aav
test
hela
cell
atcc
usa
use
fluoresc
microscopi
flow
cytometri
analysi
purifi
viru
serial
dilut
serumfre
medium
ad
cell
cultur
seed
tissu
cultur
plate
day
infect
fresh
dmem
suppli
fc
ad
h
later
continu
cultur
day
h
cultur
cell
express
hrgfp
observ
fluoresc
microscopi
olympu
usa
infect
rate
aav
differ
cell
line
also
monitor
detect
percentag
cell
express
hrgfp
use
flow
cytomet
facscalibur
bd
usa
immunofluoresc
assay
perform
detect
rbd
express
infect
hela
cell
briefli
cell
infect
particl
rbdraav
blank
aav
fresh
dmem
suppli
fc
ad
h
later
continu
cultur
h
infect
cell
fix
paraformaldehyd
incub
mcab
kindli
provid
dr
b
sun
shanghai
institut
biolog
scienc
chines
academi
scienc
dilut
h
room
temperatur
follow
three
wash
pb
incub
peconjug
goat
antimous
igg
ebiosci
usa
min
wash
cell
detect
fluoresc
express
rbd
protein
also
detect
western
blot
analysi
briefli
rbdraav
blank
aavinfect
hela
cell
harvest
h
infect
cell
wash
three
time
pb
lyze
cell
lysi
buffer
mm
tri
ph
mm
nacl
sd
mm
edta
glycerol
proteas
inhibitor
cocktail
roch
usa
express
rbd
separ
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
transfer
nitrocellulos
membran
amersham
bioscienc
usa
blot
block
overnight
skim
milk
pb
contain
tween
pbst
follow
incub
dilut
h
room
temperatur
blot
wash
three
time
incub
hrpconjug
goat
antimous
igg
dako
denmark
h
room
temperatur
signal
visual
ecl
western
blot
substrat
reagent
amersham
bioscienc
usa
kodak
biomax
scientif
imag
film
eastman
kodak
femal
balbc
mice
age
week
use
vaccin
mice
separ
group
mice
group
intramuscularli
im
vaccin
respect
one
dose
particl
pb
rbdraav
one
dose
particl
pb
blank
aav
one
dose
protein
pb
inactiv
sarscov
without
adjuv
alum
prepar
describ
qu
et
al
three
dose
rbdraav
second
dose
week
third
dose
month
three
dose
blank
aav
control
group
three
dose
inactiv
sarscov
without
alum
interv
three
dose
pb
control
group
mous
sera
collect
month
postvaccin
group
month
postimmun
group
retroorbit
punctur
diethyl
ether
anesthesia
specif
antibodi
sarscov
mous
sera
test
enzymelink
immunosorb
assay
elisa
use
commerci
sarscov
antibodi
detect
kit
beij
genom
institut
beij
china
briefli
serial
dilut
mous
sera
ad
microtit
plate
coat
protein
mixtur
sarscov
viral
lysat
plate
incub
min
follow
four
wash
pbst
bound
antibodi
react
hrpconjug
goat
antimous
igg
dako
denmark
min
four
wash
substrat
tmb
zyme
usa
ad
plate
reaction
stop
ad
n
h
absorb
nm
measur
elisa
plate
reader
victor
multilabel
counter
perkinelm
usa
titer
neutral
antibodi
mous
sera
immun
rbdraav
blank
aav
inactiv
viru
detect
vero
cell
describ
qu
et
al
briefli
vero
cell
seed
cell
per
well
cultur
plate
grown
overnight
serial
dilut
serum
sampl
separ
mix
tcid
tissuecultur
infecti
dose
sarscov
strain
genbank
access
incub
h
ad
monolay
vero
cell
assay
viru
backtitr
viru
serial
dilut
medium
viru
posit
control
tcid
neg
cell
control
medium
also
includ
parallel
neutral
test
cytopath
effect
cpe
observ
daili
endpoint
read
record
day
postinfect
neutral
antibodi
titer
determin
base
highest
dilut
serum
complet
suppress
cpe
induc
viru
inhibitori
effect
mous
antisera
rbd
bind
receptor
test
elisa
assay
et
al
et
al
briefli
recombin
solubl
r
system
coat
microtit
plate
concentr
carbon
buffer
ph
incub
overnight
block
skim
milk
rbdfc
ad
well
presenc
absenc
dilut
sera
rbdraav
blank
aavvaccin
mice
incub
h
plate
wash
twice
pbst
incub
hrpconjug
goat
antihuman
igg
zyme
usa
h
follow
ad
substrat
tmb
detect
valu
present
mean
standard
error
se
statist
signific
rbdraav
inactiv
sarscov
singl
repeat
vaccin
calcul
student
test
use
stata
statist
softwar
p
valu
less
consid
signific
